Introduction. In the treatment of acute phase ischemic stroke, tPA has high risk of hemorrhage which is usually fatal, and the treatment time window is very narrow. Therefore, the search for alternatives to tPA that can reduce hemorrhagic risk and lengthen treatment time window is an urgent priority. The recent studies report recombinant annexin 2 (rAN2) amplifies tPA converted plasmin generati...

BACKGROUND AND PURPOSE Recent randomized clinical trials (RCTs) have demonstrated benefits of endovascular recanalization therapy (ERT) contrary to earlier trials. We aimed to estimate the benefits of ERT added to standard therapy in acute ischemic stroke. METHODS From a literature search of RCTs testing ERT, we performed a meta-analysis to estimate an overall efficacy and safety of ERT for a...

BACKGROUND AND PURPOSE The Third European Cooperative Acute Stroke Study (ECASS-3) demonstrated a benefit of treatment with intravenous tissue plasminogen activator (tPA) for acute stroke in the 3- to 4.5-hour time-window. Prior studies, however, have failed to demonstrate a significant benefit of tPA for patients treated beyond 3 hours. The purpose of this study was to produce reliable and pre...

The phorbol ester 12-CMetradecanoylphorbol-13-acetate (TPA) in duces macrophage-like differentiation of 111 60 cells and cells from patients with acute nonlymphocytic leukemia (ANLL). We assessed the use of TPA as a means of eradicating residual leukemia from remission bone marrow prior to autologous bone marrow reconstitution. A 30-min incubation with TPA led to marked growth arrest in III.60 ...

Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intra...

BACKGROUND AND PURPOSE Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. METHODS We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours ...

The purpose of this report is to review the Fred Hutchinson Cancer Research Center experience of treating patients with venocclusive disease of the liver (VOD) after marrow transplantation using recombinant human tissue plasminogen activator (rh-tPA) and heparin. The charts of 42 patients who had received rh-tPA and heparin for the treatment of VOD between February 1991 and December 1995 were r...

BACKGROUND AND PURPOSE Our objective was to use decision analytic modeling to compare 2 treatment strategies of intravenous recombinant tissue-type plasminogen activator (r-tPA) alone versus combined intravenous r-tPA/endovascular therapy in a subgroup of patients with large vessel (internal carotid artery terminus, M1, and M2) occlusion based on varying times to angiographic reperfusion and va...

BACKGROUND The aim of this study was to examine and compare the value of the serum tumor markers CYFRA 21-1, TPA-M, SCCA and CEA in squamous cell carcinoma (SCC) of the larynx. Moreover, their possible clinical applications were studied. MATERIALS AND METHODS The serum levels of CYFRA 21-1, TPA-M, SCCA and CEA were measured in 79 patients with histologically-proven squamous cell carcinoma (SC...

Background and Purpose—Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods—We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of...